Olopatadine 0.7% Eye Drops Approved for Sale Over-the-Counter
The FDA has approved Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride 0.7%; Alcon) ophthalmic solution, formerly prescribed as Pazeo®, for sale over-the-counter.
Home
Tremfya Approved for Active Psoriatic Arthritis
The FDA has approved Tremfya® (guselkumab; Janssen) for the treatment of adult patients with active psoriatic arthritis.
FDA: Several Companies Recall Metformin ER Over NDMA Concerns
Several companies have initiated recalls of metformin extended-release tablets due to the possibility of unacceptable levels of N-Nitrosodimethylamine, a probable human carcinogen.
Baloxavir Protects Household Contacts From Influenza
Percentage of patients in whom clinical influenza developed significantly lower in baloxavir group.
FDA Expands Use of Botox and Dysport for Spasticity in Pediatric Patients
The FDA has approved the expanded use of Botox® (onabotulinumtoxinA; Allergan) for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by cerebral palsy.
ProAir Digihaler, a Rescue Inhaler With Built-In Sensors, Now Available
ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB).
Avacopan NDA Submitted for ANCA-Associated Vasculitis
ChemoCentryx, Inc has submitted a NDA to the Food and Drug Administration (FDA) for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Comparative Analysis Shows Remdesivir Cuts Death Risk in Severe COVID-19
Treatment with remdesivir was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality in patients with severe coronavirus disease 2019.
FDA Fast-Tracks Two mRNA-Based COVID-19 Vaccine Candidates
The FDA has granted Fast Track designation to 2 of Pfizer and BioNTech’s vaccine candidates against COVID-19.
Risk for COVID-19 Increased for Adults Taking PPIs
Dose-response relationship observed; risk up 3.67-fold for those using PPIs up to twice daily.
Want to read more?
Please login or register first to view this content.
